Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

33.34
-0.4100-1.21%
Volume:152.98K
Turnover:5.14M
Market Cap:2.47B
PE:504.88
High:33.97
Open:33.74
Low:33.30
Close:33.75
52wk High:34.55
52wk Low:17.82
Shares:74.11M
Float Shares:33.55M
Volume Ratio:0.47
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0660
EPS(LYR):-0.6047
ROE:1.03%
ROA:0.46%
PB:4.99
PE(LYR):-55.13

Loading ...

Kiniksa Pharmaceuticals COO Eben Tessari Reports Disposal of Common Shares

Reuters
·
Aug 21

How Investors May Respond To Kiniksa Pharmaceuticals (KNSA) Profit Surge and Upward Revenue Guidance

Simply Wall St.
·
Aug 12

The Bull Case For Kiniksa Pharmaceuticals (KNSA) Could Change Following Upbeat Profit and Revenue Outlook

Simply Wall St.
·
Aug 09

John F. Paolini, Chief Medical Officer, Reports Disposal of Kiniksa Pharmaceuticals Common Shares

Reuters
·
Aug 09

AI Play Arista Hits Record High, Joins 3 Best Stock Lists: Build Your Growth Stock Watchlist With These Just Updated Screens

Blockhead
·
Aug 07

Kiniksa Pharmaceuticals (KNSA) Is Up 18.3% After Strong Q2 Earnings and Raised 2025 Guidance – Has the Bull Case Changed?

Simply Wall St.
·
Aug 05

Stock Track | Kiniksa Pharmaceuticals Soars 5% on Strong Q2 Earnings and Raised Guidance

Stock Track
·
Aug 02

Just The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% Run

Blockhead
·
Aug 02

Why Kiniksa Pharmaceuticals (KNSA) Is Up 12.5% After Reporting Q2 Profitability and Raising Revenue Guidance

Simply Wall St.
·
Aug 01

Kiniksa Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
Jul 30

Kiniksa price target raised to $54 from $45 at Jefferies

TIPRANKS
·
Jul 30

Kiniksa Pharma Shares Climb After Swinging to 2Q Profit, Posting Higher Sales

Dow Jones
·
Jul 29

Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-market on Strong Q2 Results and Raised Revenue Guidance

Stock Track
·
Jul 29

Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-Market on Q2 Earnings Beat and Raised 2025 Guidance

Stock Track
·
Jul 29

Kiniksa Pharmaceuticals Q2 EPS USD 0.24

Reuters
·
Jul 29

Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q2 EPS $0.23, vs. FactSet Est of $0.22

MT Newswires Live
·
Jul 29

Kiniksa Pharmaceuticals' ARCALYST 2025 Expected Net product Revenue Guidance Increased To $625M-$640M Compared To Prior Guidance Of $590M-$605M

Benzinga
·
Jul 29

Kiniksa Pharmaceuticals Q2 2025 EPS $0.23 Beats $0.18 Estimate, Sales $156.797M Beat $145.218M Estimate

Benzinga
·
Jul 29

Kiniksa Pharmaceuticals Reports 52% Increase in ARCALYST Q2 Net Product Revenue, Achieves $17.8M Net Income

Reuters
·
Jul 29

Kiniksa Pharmaceuticals International: Kpl-387 Phase 2/3 Clinical Trial in Recurrent Pericarditis Initiated; Phase 2 Data Expected in 2H 2026

THOMSON REUTERS
·
Jul 29